| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer | President, Spacelabs Healthcare
2 companies
James W Green last filed a Form 4 in August 2025, as Director at HBIO. The filings on record cover 2 companies. James W Green's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, James W Green's trades have earned a strong insider score of 70/100 across 17 rated trades. Over a 12-month horizon, 82.4% of those trades were profitable, with an average 12-month return of +31.1%.
At the last filing, the largest reported position was 2,452,566 shares of HBIO. Net of sales, the HBIO filings show accumulation of 74,473 shares.
James W Green has 58 Form 4 filings on record from May 2015 to August 2025, across 2 companies: Director at Harvard Bioscience (HBIO), 2015–2025; President, Spacelabs Healthcare at Osi Systems (OSIS), 2018–2019.
The 95 reported transactions were 30 stock awards, 27 tax withholdings, 17 open-market purchases and 8 dispositions back to the company, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 14 purchases worth about $896K and 5 sales worth about $1.4M.
The largest open-market purchase was 40,000 shares of HBIO at an average $3.69 on May 9, 2022, about $147K. Twelve months later HBIO was up 67%.
The largest open-market sale was 48,175 shares of HBIO at an average $8.02 on August 23, 2021, about $386K. Twelve months later HBIO was down 61%.
Shares as reported in the last Form 4 for each company; the most recent is from August 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 13, 2024 | HBIO Harvard Bioscience Inc | Chief Executive Officer | Buy | 10,000 | $2.91 | $29,100.00 | +0.3% | -2.7% | -82.5% | |
| Jun 6, 2024 | HBIO Harvard Bioscience Inc | Chief Executive Officer | Buy | 20,000 | $3.07 | $61,400.00 | +0.6% | -7.7% | -86.3% | |
| Aug 17, 2023 | HBIO Harvard Bioscience Inc | Chief Executive Officer | Buy | 25,000 | $4.38 | $109,500.00 | +0.9% | -1.8% | -31.9% | |
| Mar 15, 2023 | HBIO Harvard Bioscience Inc | Chief Executive Officer | Buy | 40,000 | $2.64 | $105,400.00 | +1.4% | +119.7% | +62.5% | |
| Dec 1, 2022 | HBIO Harvard Bioscience Inc | Chief Executive Officer | Buy | 30,000 | $2.51 | $75,300.00 | +1.3% | -1.8% | +58.8% | |
| Aug 17, 2022 | HBIO Harvard Bioscience Inc | Chief Executive Officer | Buy | 40,000 | $3.19 | $127,600.00 | +1.8% | -24.8% | +35.7% | |
| Jun 15, 2022 | HBIO Harvard Bioscience Inc | Chief Executive Officer | Buy | 30,000 | $3.71 | $111,300.00 | +1.3% | -15.0% | +48.2% | |
| May 9, 2022 | HBIO Harvard Bioscience Inc | Chief Executive Officer | Buy | 40,000 | $3.69 | $147,400.00 | +1.8% | -0.9% | +67.3% | |
| Aug 23, 2021 | HBIO Harvard Bioscience Inc | Chief Executive Officer | Sell | 48,175 | $8.02 | $386,363.50 | -2.3% | -10.5% | -60.7% | |
| May 21, 2021 | HBIO Harvard Bioscience Inc | Chief Executive Officer | Sale+OE | 24,312 | $7.14 | $173,587.68 | -1.1% | +16.5% | -48.5% |